Hexarelin Acetate

Stereochemically defined GHSR agonist hexapeptide (hexarelin/examorelin)

Per batch COACAS 140703-51-1RUO

Research statusEarly human endocrine pharmacology plus preclinical mechanistic literature; no approved therapeutic use; laboratory Research Use Only reference context · supplied material is RUO

Supplied formAmidated six-residue peptide with D-2-methyltryptophan and D-phenylalanine

Lead timeConfirmed with quote

Hexarelin Acetate — Lyophilized material; confirm released-lot appearance on the COA

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research value: a compact stereochemically defined GHRP enables studies of GHSR signaling, GH-response pharmacology, receptor desensitization, CD36 binding and model-specific cardiovascular, mitochondrial or stress-response pathways
These research contexts do not establish therapeutic benefit, athletic performance, recovery or body-composition effects for an RUO lot.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 140703-51-1
Formula: Confirm supplied form on batch COA
Molecular weight: 887.0 g/mol
Appearance: Lyophilized material; confirm released-lot appearance on the COA
Purity: Per batch COA
Storage: Use the released-lot COA and stability statement for the supplied acetate/counterion state. Define temperature, moisture and light protection, container closure, freeze-thaw allowance, solvent and concentration; do not infer solution life from generic vendor claims.
MOQ: On request
Lead time: Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Hexarelin Acetate

Hexarelin (examorelin) is the synthetic amidated hexapeptide H-His-D-Trp(2-Me)-Ala-Trp-D-Phe-Lys-NH2 and a growth-hormone secretagogue receptor agonist studied in early endocrine pharmacology. PubChem CID 6918297 defines the free-peptide record. Cardiovascular research identifies CD36 binding and GHSR-related effects in animal and tissue models, while muscle and neuroprotection studies remain preclinical. Hexarelin is not an FDA-approved drug. WADA's 2026 Prohibited List names examorelin (hexarelin) among GH-releasing peptides prohibited at all times for athletes subject to the Code. This catalog material is an RUO analytical/research reagent, not a finished dosage form.

Evidence contexts include GHSR-mediated endocrine signaling and GH response in early human studies
CD36/GHSR cardiovascular mechanisms in animal and tissue models; and exploratory muscle-mitochondrial and cellular stress-response research
Model evidence must not be represented as human cardioprotection, neuroprotection, recovery or metabolic benefit.

Mechanism context

The question the literature is testing

Hexarelin acts as a growth-hormone secretagogue receptor agonist in endocrine systems, with downstream signaling that promotes GH release. A 2002 Circulation Research study identified CD36 as a cardiac hexarelin-binding protein and showed CD36-dependent coronary vasoconstrictive responses in perfused animal hearts. Separate rat ischemia-reperfusion work reported injury-marker changes that were blocked by a GHSR antagonist. These model-specific findings support more than one target hypothesis but do not establish a single human cardioprotective mechanism.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context

Research areaGrowth-hormone axis research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Hexarelin is not FDA approved
Early human endocrine studies and preclinical literature do not establish long-term safety or clinical benefit for independently supplied material
WADA lists examorelin (hexarelin) as prohibited at all times for athletes subject to the Code

Interactions reported in the literature

No stacking or combination-use guidance is provided
Any combination experiment requires a prespecified protocol, controls, concentration justification and institutional risk review; vendor pairing claims are not evidence.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Hexarelin Acetate factory batch COAs

Hexarelin Acetate 2 mg Factory batch COA protected preview

Hexarelin Acetate2 mg · WHJLP-HX2-260423-D

Hexarelin Acetate 5 mg Factory batch COA protected preview

Hexarelin Acetate5 mg · WHJLP-HX5-260423-D

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require the stereochemically defined complete sequence and terminal amidation, high-resolution intact mass, an orthogonal identity method, peptide-content assay, chromatographic purity with impurity assignment, counterion/acetate quantitation, water, residual solvents and aggregate assessment
A nominal >98% HPLC area result, vial appearance or CAS number alone does not establish content or salt composition.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

HEXA-2MG2 mg10 vials

HEXA-5MG5 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Use the released-lot COA and stability statement for the supplied acetate/counterion state. Define temperature, moisture and light protection, container closure, freeze-thaw allowance, solvent and concentration; do not infer solution life from generic vendor claims.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Key primary sources: PubChem CID 6918297; WADA 2026 Prohibited List; Deghenghi et al. 1994 (PMID 8028453); Ghigo et al. 1994 (PMID 8126144); Imbimbo et al. 1994 (PMID 7957536); Loche et al. 1995 (PMID 7673411); Torsello et al. 1996 (PMID 8921832); Bodart et al. 1999 (PMID 10532947); Bodart et al. 2002 (PMID 11988484); Mao et al. 2014 (PMID 25278975); the cited 2017 ischemia-reperfusion and cachexia studies; and Meanti et al. 2023 (PMID 36674509). Human, animal and cell evidence are labelled separately in the literature section.

01
GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats
Life Sciences · 1994 · peer-reviewed original research (foundational discovery paper)
Open source
02
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man
Journal of Clinical Endocrinology & Metabolism · 1994 · peer-reviewed original research (clinical pharmacology, dose/route comparison)
Open source
03
Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat
European Journal of Endocrinology · 1996 · peer-reviewed original research (mechanism of action)
Open source
04
The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency
Journal of Clinical Endocrinology & Metabolism · 1995 · peer-reviewed original research (clinical trial, GH deficiency)
Open source
05
Does desensitization to hexarelin occur?
Growth Hormone & IGF Research · 1998 · peer-reviewed original research (tachyphylaxis/desensitization study)
Open source
06
Identification and characterization of a new growth hormone-releasing peptide receptor in the heart
Circulation Research · 1999 · peer-reviewed original research (receptor pharmacology)
Open source
07
CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart
Circulation Research · 2002 · peer-reviewed original research (receptor identification, landmark mechanism paper)
Open source
08
GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy
European Journal of Heart Failure · 2002 · peer-reviewed original research (human clinical study, cardiac patients)
Open source

Product FAQ

Questions buyers ask about Hexarelin Acetate

What identity details should an order specification include for Hexarelin Acetate?+

Specify the complete stereochemical sequence H-His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂, C-terminal amidation and the required counterion state. PubChem CID 6918297 and CAS 140703-51-1 describe the free-peptide record; an acetate-labelled lot can have a different gross composition. The batch documents should report peptide content and measured acetate or other counterions rather than relying on the product name or CAS alone.

Which batch tests are especially important for Hexarelin?+

Request high-resolution intact mass, an orthogonal identity or sequence method capable of confirming the two D-residues and 2-methyltryptophan, terminal-amidation confirmation, chromatographic purity with impurity assignment and a separate peptide-content assay. Also define acetate or other counterions, water, residual solvents, storage and retest conditions. HPLC area purity and vial appearance alone do not establish stereochemical identity, peptide content or salt composition.

Hexarelin Acetate

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Hexarelin Acetate

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Hexarelin Acetate factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats

Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat

The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency

Does desensitization to hexarelin occur?

Identification and characterization of a new growth hormone-releasing peptide receptor in the heart

CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart

GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy

Questions buyers ask about Hexarelin Acetate

Compare adjacent molecules and documentation needs.

Sermorelin

GHRP-2

Tesa+IP5

AOD-9604